GAVISCON DOUBLE ACTION MINT

For oral administration. Adults and children 12 years and over: 10-20 ml after meals and at bedtime, up to four times per day.

Children under 12 years:

Should be given only on medical advice.

Elderly:

No dose modifications necessary for this age group.

Hepatic Impairment:

No dose modification necessary. 4).

Adverse events which have been associated with sodium alginate, sodium bicarbonate and calcium carbonate are given below, tabulated by system organ class and frequency.

Frequencies are defined as:

Very common (≥1/10); Common (≥1/100 and <1/10); Uncommon (≥1/1000 and <1/100); Rare (≥1/10,000 and <1/1000); Very rare (< 1/10,000); Not known (cannot be estimated from the available data). Within each frequency grouping, adverse events are presented in order of decreasing seriousness.

System Organ Class Frequency Adverse Events Immune System Disorders Very Rarely Anaphylactic reaction, anaphylactoid reaction. Hypersensitivity reactions such as urticaria. Metabolism and Nutritional Disorders Not Known Alkalosis1, acid rebound1, Hypercalcaemia1, Milk-alkali System Organ Class Frequency Adverse Events Syndrome1 Respiratory, Thoracic and Mediastinal Disorders Very Rarely Respiratory effects such as bronchospasm.

Gastrointestinal Disorders Not Known Constipation1 Description of Selected Adverse Reactions 1 Usually occurs following larger than recommended dosages. Reporting of Suspected Adverse Reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4% of the WHO recommended maximum daily intake for sodium. 15% of the WHO recommended maximum daily intake for sodium. This product is considered high in sodium. g. in some cases of congestive heart failure and renal impairment). 5 mmol) of calcium.

Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi. Treatment of children younger than 12 years of age is not generally recommended, except on medical advice.

If symptoms persist, or treatment is required for more than 7 days continuously, medical advice should be sought. As with other antacid products, taking this product can mask the symptoms of other more serious, underlying medical conditions.

Contains methyl parahydroxybenzoate (E218) 40 mg/ 10ml and propyl parahydroxybenzoate (E216) 6 mg/10ml which may cause allergic reactions (possibly delayed).

1. This product should not be used in patients with moderate or severe renal insufficiency